Toshimasa Yamauchi

Professor

Graduate School of Medicine, The University of Tokyo
Country flagJapan
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Background While behavioral interventions remain an evidence-based treatment for obesity, they often require long durations and frequent sessions. To address this, we hypothesized that interventions delivered in daily life via a smartphone app combined with personalized optimization using reinforcement learning may effectively support behavior changes. Objective This study aimed to develop and evaluate the feasibility of such an app for individuals with obesity. Methods We developed a smartphone app to assist in setting and reviewing daily behaviors related to weight loss. On the screen on which daily behaviors were shown, the order of presentation was optimized using Thompson sampling, a multiarmed bandit algorithm. Twenty individuals with obesity used the app for 4 weeks, and the daily app use rates were quantified. Body weight and mood status were measured daily during the study, and a brief-type self-administered diet history questionnaire and the International Physical Activity Questionnaire were administered at the beginning and end of the study. Changes in these measures were evaluated using the Wilcoxon signed rank test. Furthermore, the longitudinal data collected during this study were analyzed using a linear mixed-effects model to examine factors related to the number of behaviors performed daily. Results All 20 recruited individuals with obesity completed the 4-week study schedule. The median app use rate was 98.3% (range 76.9%‐100%). Significant improvements were observed in BMI (median at start 34.9 kg/m 2 , range 27.4-52.9; median at end 34.1 kg/m 2 , range 26.7‐51.0; P =.01), as well as daily energy intake and weekend sitting time. The linear mixed-effects model showed a significant association between higher preceding depressive mood levels and fewer behaviors ( P <.001). Conclusions The feasibility of the smartphone app using reinforcement learning for obesity was sufficient, and the potential effectiveness of the treatment was suggested. Preceding depressive mood may influence daily behaviors related to weight loss.

Year:

2026

Background A high intake of dietary fiber has been shown to improve glycemic control and decrease hyperinsulinemia in people living with type 2 diabetes (T2D). T2D patients in Japan consume less than the recommended amount of fiber. Based on findings from a formative study, we developed an artificial intelligence (AI)-powered mobile health (mHealth) intervention, FiberMore, that uses the theory of planned behavior to help T2D patients increase their dietary fiber intake by enhancing their perceived behavioral control and attitude toward fiber consumption. Objective We aimed to assess the efficacy of FiberMore in improving the dietary fiber intake of T2D patients by conducting a pilot randomized controlled trial. In addition, we want to explore the efficacy of FiberMore in reducing HbA 1c of T2D patients via improvement in dietary fiber intake. Methods This is a randomized, single-blinded, multicenter study targeting 80 T2D patients from 3 institutions in Japan with a 2-week run-in, a 12-week intervention, and a 12-week observation. The intervention group is given access to FiberMore throughout the 12-week intervention period. A core feature of FiberMore is AI-powered meal photo logging using a fine-tuned GPT-4o (OpenAI) model, which analyzes the nutrient content of meals and delivers personalized, real-time feedback on fiber content. In addition, FiberMore provides personalized fiber goal setting and supports participants in identifying barriers to increasing fiber intake, along with corresponding coping strategies (labeled as “solutions” to the participant), through an AI chatbot. The AI chatbot also assesses participants’ emotional attitudes toward eating more fiber and delivers relevant educational content on dietary fiber. The control group receives a sham intervention focused on salt reduction, consisting of educational content delivered at 3 time points during the intervention period and records their daily efforts in salt reduction in a diary. The 12-week intervention period will be followed by a 12-week observational period to investigate the sustainability of the intervention’s effects. The primary outcome is between-group difference in the change of dietary fiber intake at 12 weeks. The secondary outcomes include HbA1c, other clinical measures, measurements of behavior changes, and assessment of participants’ satisfaction and perceived usefulness of the intervention. Results Recruitment began on February 12, 2025, and ended on September 1, 2025. We anticipate that the intervention period will conclude in December 2025 and the observation period will conclude in March 2026. As of September 22, 2025, a total of 72 participants have been officially enrolled and randomized. Conclusions: There are currently no mHealth dietary interventions that specifically focus on increasing fiber intake in Japan, highlighting the novelty of this intervention. This trial will generate important evidence on the efficacy, feasibility, and safety of an AI-based mHealth intervention for enhancing dietary fiber intake and glycemic control in free-living individuals with T2D. Furthermore, as a pilot study, it will offer valuable insights into the development of AI as a promising tool for accurate, low-burden dietary assessment.

Year:

2025

Background A 12-week pilot of the StepAdd mobile health (mHealth) behavior change intervention based on social cognitive theory (SCT) saw an 86.7% increase in mean daily step counts among patients with type 2 diabetes. Due to the lack of exploration of theoretical implications in mHealth intervention studies, there is a need to understand the mechanism underlying the behavioral change to inform the future design of digital therapeutics. Objective This study aimed to examine the SCT drivers underlying the mean increase in exercise among Japanese patients with type 2 diabetes who participated in the StepAdd intervention. Methods This is a post hoc analysis of data collected in the single-arm pilot study of the 32 patients who completed the StepAdd intervention. The StepAdd app uses self-mastery and coping strategies to increase self-efficacy and thus increase walking. Self-mastery was measured by the goal completion (GC) rate, which is the percentage of days in which patients met these adapting goals. The use of coping strategies was measured by the strategy implementation (SI) rate, which is the percentage of days in which patients applied their selected coping strategies. We assessed correlations between GC, SI, and self-efficacy to increase walking via linear regression and analyzed relationships via structural equation modeling. Results We found statistically significant support for the SCT approach, including a correlation coefficient (ρ) of 0.649 between step increase and GC rate ( P <.001); a ρ of 0.497 between the coping SI rate and self-efficacy increase ( P =.004); a ρ of 0.446 between GC rate and self-mastery increase ( P =.01); and a ρ of 0.355 between self-regulation increase and step increase ( P =.046), giving us insight into why the behavior intervention succeeded. We also found significant correlations between self-efficacy for barriers and self-efficacy for task-specific behavior (ρ=0.358; P =.04), as well as self-regulation and self-efficacy for task-specific behavior (ρ=0.583; P <.001). However, a cross-lagged panel modeling analysis found no significant evidence that changes in self-efficacy preceded behavior changes in line with SCT. Conclusions Self-mastery and coping strategies contributed to the walking behavior change in StepAdd, supporting the SCT model of behavior change. Future research is needed to better understand the causal pathways proposed by SCT.

Year:

2025

UNSTRUCTURED Reduced or delayed medical follow-ups have been reported during the COVID-19 pandemic, which may lead to worsening clinical outcomes for patients with diabetes. The Japanese government granted special permission for medical institutions to use telephone consultations and other remote communication modes during the COVID-19 pandemic. We aimed to evaluate changes in the frequency of outpatient consultations, glycemic control, and renal function among patients with type 2 diabetes before and during the COVID-19 pandemic. This is a retrospective single-cohort study conducted in Tokyo, Japan, analyzing results for 3035 patients who visited the hospital regularly. We compared the frequency of outpatient consultations attended (both in person and via telemedicine phone consultation), glycated hemoglobin A1c (HbA1c), and estimated glomerular filtration rate (eGFR) among patients with type 2 diabetes mellitus during the 6 months from April 2020 to September 2020 (ie, during the COVID-19 pandemic) with those during the same period of the previous year, 2019, using Wilcoxon signed rank tests. We conducted a multivariate logistic regression analysis to identify factors related to the changes in glycemic control and eGFR. We also compared the changes in HbA1c and eGFR from 2019 to 2020 among telemedicine users and telemedicine nonusers using difference-in-differences design. The overall median number of outpatient consultations attended decreased significantly from 3 (IQR 2-3) in 2019 to 2 (IQR 2-3) in 2020 (P<.001). Median HbA1c levels deteriorated, though not to a clinically significant degree (6.90%, IQR 6.47%-7.39% vs 6.95%, IQR 6.47%-7.40%; P<.001). The decline in median eGFR was greater during the year 2019-2020 compared to the year 2018-2019 (–0.9 vs –0.5 mL/min/1.73 m2; P=.01). Changes in HbA1c and eGFR did not differ between patients who used telemedicine phone consultations and those who did not. Age and HbA1c level before the pandemic were positive predictors of worsening glycemic control during the COVID-19 pandemic, whereas the number of outpatient consultations attended was identified as a negative predictor of worsening glycemic control during the pandemic. The COVID-19 pandemic resulted in reduced attendance of outpatient consultations among patients with type 2 diabetes, and these patients also experienced deterioration in kidney function. Difference in consultation modality (in person or by phone) did not affect glycemic control and renal progression of the patients.

Year:

2025

BACKGROUND A strong association exists between sleep duration and glycemic control in patients with type 2 diabetes (T2D), yet convincing evidence of a causal link remains lacking. Improving sleep is increasingly emphasized in clinical T2D treatment guidance, highlighting the need for effective, scalable sleep interventions that can affordably serve large populations through mobile health (mHealth). OBJECTIVE This study aims to pilot an intervention that extends sleep duration by modifying bedtime behavior, assessing its efficacy among short-sleeping (≤6 hours per night) patients with T2D, and establishing robust evidence that extending sleep improves glycemic control. METHODS This randomized, single-blinded, multicenter study targets 70 patients with T2D from 9 institutions in Japan over a 12-week intervention period. The sleep extension intervention, BedTime, is developed using the Theory of Planned Behavior (TPB) and focuses on TPB’s constructs of perceived and actual behavioral control (ABC). The pilot intervention combines wearable actigraphy devices with SMS text messaging managed by human operators. Both the intervention and control groups will use an actigraphy device to record bedtime, sleep duration, and step count, while time in bed (TIB) will be assessed via sleep diaries. In addition, the intervention group will receive weekly bedtime goals, daily feedback on their bedtime performance relative to those goals, identify personal barriers to an earlier bedtime, and select strategies to overcome these barriers. The 12-week intervention period will be followed by a 12-week observational period to assess the sustainability of the intervention’s effects. The primary outcome is the between-group difference in the change in hemoglobin A 1c (HbA 1c ) at 12 weeks. Secondary outcomes include other health measures, sleep metrics (bedtime, TIB, sleep duration, total sleep time, and sleep quality), behavioral changes, and assessments of the intervention’s usability. The trial commenced on February 8, 2024, and is expected to conclude in February 2025. RESULTS Patient recruitment ended on August 29, 2024, with 70 participants enrolled. The intervention period concluded on December 6, 2024, and the observation period ended on February 26, 2025, with 70 participants completing the observation period. The data analysis is currently underway, and results are expected to be published in July 2025. CONCLUSIONS This trial will provide important evidence on the causal link between increased sleep duration and improved glycemic control in short-sleeping patients with T2D. It will also evaluate the efficacy of our bedtime behavior change intervention in extending sleep duration, initially piloted with human operators, with the goal of future implementation via an mHealth smartphone app. If proven effective, this intervention could be a key step toward integrating sleep-focused mHealth into the standard treatment for patients with T2D in Japan. CLINICALTRIAL Japan Registry of Clinical Trials jRCT1030230650; https://jrct.niph.go.jp/latest-detail/jRCT1030230650 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/64023

Year:

2024

BACKGROUND The iAide2 (Tokai) physical activity monitoring system includes diverse measurements and wireless features useful to researchers. The iAide2’s sleep measurement capabilities have not been compared to validated sleep measurement standards in any published work. OBJECTIVE We aimed to assess the iAide2’s sleep duration and total sleep time (TST) measurement performance and perform calibration if needed. METHODS We performed free-living sleep monitoring in 6 convenience-sampled participants without known sleep disorders recruited from within the Waki DTx Laboratory at the Graduate School of Medicine, University of Tokyo. To assess free-living sleep, we validated the iAide2 against a second actigraph that was previously validated against polysomnography, the MotionWatch 8 (MW8; CamNtech Ltd). The participants wore both devices on the nondominant arm, with the MW8 closest to the hand, all day except when bathing. The MW8 and iAide2 assessments both used the MW8 EVENT-marker button to record bedtime and risetime. For the MW8, MotionWare Software (version 1.4.20; CamNtech Ltd) provided TST, and we calculated sleep duration from the sleep onset and sleep offset provided by the software. We used a similar process with the iAide2, using iAide2 software (version 7.0). We analyzed 64 nights and evaluated the agreement between the iAide2 and the MW8 for sleep duration and TST based on intraclass correlation coefficients (ICCs). RESULTS The absolute ICCs (2-way mixed effects, absolute agreement, single measurement) for sleep duration (0.69, 95% CI –0.07 to 0.91) and TST (0.56, 95% CI –0.07 to 0.82) were moderate. The consistency ICC (2-way mixed effects, consistency, single measurement) was excellent for sleep duration (0.91, 95% CI 0.86-0.95) and moderate for TST (0.78, 95% CI 0.67-0.86). We determined a simple calibration approach. After calibration, the ICCs improved to 0.96 (95% CI 0.94-0.98) for sleep duration and 0.82 (95% CI 0.71-0.88) for TST. The results were not sensitive to the specific participants included, with an ICC range of 0.96-0.97 for sleep duration and 0.79-0.87 for TST when applying our calibration equation to data removing one participant at a time and 0.96-0.97 for sleep duration and 0.79-0.86 for TST when recalibrating while removing one participant at a time. CONCLUSIONS The measurement errors of the uncalibrated iAide2 for both sleep duration and TST seem too large for them to be useful as absolute measurements, though they could be useful as relative measurements. The measurement errors after calibration are low, and the calibration approach is general and robust, validating the use of iAide2’s sleep measurement functions alongside its other features in physical activity research.

Year:

2024

Background Increasing physical activity improves glycemic control in patients with type 2 diabetes (T2D). Mobile health (mHealth) interventions have been proven to increase exercise, but engagement often fades with time. As the use of health behavior theory in mHealth design can increase effectiveness, we developed StepAdd, an mHealth intervention based on the constructs of social cognitive theory (SCT). StepAdd improves exercise behavior self-efficacy and self-regulation through the use of goal-setting, barrier-identifying, and barrier-coping strategies, as well as automatic feedback functions. A single-arm pilot study of StepAdd among 33 patients with T2D showed a large increase in step count (mean change of 4714, SD 3638 daily steps or +86.7%), along with strong improvements in BMI (mean change of −0.3 kg/m2) and hemoglobin A1c level (mean change of −0.79 percentage points). Objective In this study, we aim to investigate the efficacy and safety of StepAdd, an mHealth exercise support system for patients with T2D, via a large, long, and controlled follow-up to the pilot study. Methods This is a randomized, open-label, multicenter study targeting 160 patients with T2D from 5 institutions in Japan with a 24-week intervention. The intervention group will record daily step counts, body weight, and blood pressure using the SCT-based mobile app, StepAdd, and receive feedback about these measurements. In addition, they will set weekly step count goals, identify personal barriers to walking, and define strategies to overcome these barriers. The control group will record daily step counts, body weight, and blood pressure using a non–SCT-based placebo app. Both groups will receive monthly consultations with a physician who will advise patients regarding lifestyle modifications and use of the app. The 24-week intervention period will be followed by a 12-week observational period to investigate the sustainability of the intervention’s effects. The primary outcome is between-group difference in the change in hemoglobin A1c values at 24 weeks. The secondary outcomes include other health measures, measurements of steps, measurements of other behavior changes, and assessments of app use. The trial began in January 2023 and is intended to be completed in December 2025. Results As of September 5, 2023, we had recruited 44 patients. We expect the trial to be completed by October 8, 2025, with the follow-up observation period being completed by December 31, 2025. Conclusions This trial will provide important evidence about the efficacy of an SCT-based mHealth intervention in improving physical activities and glycemic control in patients with T2D. If this study proves the intervention to be effective and safe, it could be a key step toward the integration of mHealth as part of the standard treatment received by patients with T2D in Japan. Trial Registration Japan Registry of Clinical Trials (JRCT) jRCT2032220603; https://rctportal.niph.go.jp/en/detail?trial_id=jRCT2032220603 International Registered Report Identifier (IRRID) DERR1-10.2196/53514

Year:

2024

Collaborators (14)

Seiji Nishikage

Kobe University

JAPAN
View details

Ryo Suzuki

Professor & Chairperson

Tokyo Medical and Dental University

JAPAN
View details

Kazuhiro Yoshiuchi

Associate Professor

The Univeristy of Tokyo

JAPAN
View details

Masaomi Nangaku

Graduate School of Medicine, The University of Tokyo

JAPAN
View details

Nobuhito Hirawa

Director / Associate Professor

Yokohama City University Medical Center

JAPAN
View details

Kayo Waki

Associate professor

University of Tokyo

JAPAN
View details

Yushi Hirota

Kobe University Graduate School of Medicine

JAPAN
View details

Kazuhiko Ohe

Specially Appointed Professor

Juntendo University

JAPAN
View details

Masao Toyoda

Tokai University School of Medicine

JAPAN
View details

Kouichi Tamura

Yokohama City University Graduate School of Medicine

JAPAN
View details

Masaki Igarashi

assistant professor

University of Tokyo Hospital

JAPAN
View details

Yoshiharu Yamamoto

University of Tokyo

JAPAN
View details

Hironori Waki

Professor

Akita University

JAPAN
View details

Koji Oba

University of Tokyo

JAPAN
View details